Engineering Fusion Proteins for Nanomedicine-Based Cytokine Therapy

Area of Science:

• Biotechnology
• Nanomedicine
• Immunology

Background:

• Cytokines are vital for immunity and cell communication, showing therapeutic potential for immune-mediated diseases.
• Current cytokine therapies face challenges with short blood half-lives and poor biodistribution, leading to toxicity.
• Improving cytokine pharmacokinetics is crucial for effective clinical translation.

Purpose of the Study:

• To develop a novel strategy for enhancing cytokine pharmacokinetic profiles.
• To engineer fusion proteins combining apolipoproteins and cytokines for nanoparticle formulation.
• To evaluate the stability, activity, and in vivo behavior of these novel cytokine nanoparticles.

Main Methods:

• Engineered fusion proteins by combining apolipoprotein A1 or E with interleukins 1β, 2, or 4 using recombinant methods.
• Formulated fusion proteins into apolipoprotein-based nanoparticles (cytokine-aNPs).
• Assessed nanoparticle stability, size, shape, and cytokine activity.
• Utilized zirconium-89 radiolabeling and in vivo positron emission tomography imaging in mice to track biodistribution.

Main Results:

• Recombinant expression yielded pure and biologically active fusion proteins suitable for nanoparticle formulation.
• All developed cytokine-aNPs demonstrated stability over 10 days and consistent physical characteristics.
• Cytokine activity was preserved post-purification and after nanoparticle formulation.
• In vivo imaging revealed significantly altered biodistribution of cytokine-aNPs, with preferential accumulation in spleen, bone marrow, lymph nodes, and liver compared to native cytokines.

Conclusions:

• Fusion protein technology combined with apolipoprotein-based nanoparticles (cytokine-aNPs) effectively improves the in vivo properties of cytokines.
• This approach offers a promising translational avenue for nanomedicine-based cytokine therapies.
• The enhanced biodistribution and stability of cytokine-aNPs address key limitations of traditional cytokine therapeutics.